Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 7;9:845918. doi: 10.3389/fmed.2022.845918

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Tripska, Igreja Sá, Vasinova, Vicen, Havelek, Eissazadeh, Svobodova, Vitverova, Theuer, Bernabeu and Nachtigal.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Hypothetical model of the molecular mechanisms underlying the effects of TRC105 by targeting Eng in human aortic endothelial cells under hypercholesterolemic (treated with 7-ketocholesterol [7K]) or hyperglycemic (treated with high glucose [HG]) conditions. TRC105 can inhibit: (i) the binding of the Eng ligands BMP9 and BMP10 (40); (ii) the expression of membrane-bound Eng; and (iii) the phosphorylation of Smads, which are downstream targets of Eng. TRC105 can also stimulate the protein expression of the metalloproteinase 14 (MMP-14), which in turn cleaves membrane-bound Eng and releases sEng (52).